阿斯利康：2025财年宣布的总股息提高3%，至每股3.20美元。 来源：滚动播报 ...

业绩方面，2024年以来，华润医药归母净利润持续下滑。2024年，华润医药实现营收约2577亿元，同比 增长5.3%；归母净利润约33.51亿元，同比下滑13.06%。2025年上半年，实现营收约1319亿元，同比增 长2.54%；同期归母净利润约20.77亿元，同比下滑20.30%。 据企查查，截至2026年2月10日，华润医药及其子公司华润医药投资共持有天麦生物科技23.75%股权。 其中，华润医药投资直接持股20%，系天麦生物科技的第一大股东。 此次华润医药出售其持有的天麦生物科技大部分股份，业内认为，一方面，是华润系聚焦主业剥离非核 心资产之举，另一方面，天麦生物科技重点布局的口服胰岛素上市失败也是影响因素之一。 2025年12月29日，国家药监局网站显示，天麦生物科技参股公司合肥天汇生物科技有限公司申请的重组 人胰岛素肠溶胶囊（ORMD-0801）收到药品通知件，即未能获批上市。ORMD-0801是重组人胰岛素肠 溶胶囊，口服给药，用于需要用胰岛素的糖尿病患者的治疗。该品种最初由Oramed Pharmaceutical Inc. 研发，从2015年底开始，天麦生物与Oramed Pharmaceu ...

一直以来，兴齐眼药以可持续发展为导向，积极践行ESG理念，推进相关工作全面开展，在追求企业发 展的同时，兼顾环境、社会和公司治理责任，为利益相关方创造长远价值。未来，兴齐眼药将继续 以"BRIGHT"核心ESG战略为引领，持续优化公司治理结构，规范运作，为社会和投资者持续创造价 值。 本报讯 《证券日报》记者2月10日从沈阳兴齐眼药股份有限公司（以下简称"兴齐眼药"）获悉，由思盟 企业社会责任促进中心发起，商道咨询主办的"2026CSO全球可持续发展论坛"近日在北京举行，论坛正 式发布2026CSO论坛可持续发展优秀案例评选结果，兴齐眼药凭借在履行社会责任以及在ESG实践治理 方面的优秀表现，荣获"企业ESG高效治理优秀实践案例"。 （文章来源：证券日报） ...

海翔药业发布异动公告，公司股票于2026年2月6日、2月9日、2月10日连续3个交易日收盘价格涨幅偏离 值累计超过20%。经核查，公司前期披露信息无需更正补充，经营情况正常，内外部环境未发生重大变 化；控股股东及实际控制人无应披露未披露重大事项，异动期间未买卖公司股票；截至2026年2月10 日，累计回购股份14,315,300股，占总股本0.8844%，成交总金额88,881,298.38元；参投合伙企业持有复 宏汉霖境内未上市股份已于2026年2月4日转换为H股并在香港联交所上市；2025年度业绩预告无修正情 况。声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建 议。 ...

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has had its drug registration application for Benzocaine Gel accepted by the National Medical Products Administration, marking a significant step in the company's product development [1][2]. Group 1: Company Developments - The drug, Benzocaine Gel, is a chemical product independently developed by the group [1]. - It is intended for transdermal local anesthesia, specifically for skin anesthesia prior to venipuncture or intravenous catheterization [1]. - The product is suitable for adults and infants over one month old [1]. Group 2: Regulatory Milestones - The acceptance of the drug registration application by the National Medical Products Administration is a crucial regulatory milestone for the company [2].

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while pharmaceutical distribution has the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market continues to be on GLP-1 targets, with Eli Lilly's tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches that extend into critical supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and realize cross-border cooperation milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan Biotech, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan Biotech has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The company is advancing its drug pipeline with LDR2402, a long-acting antihypertensive drug targeting AGT, which has entered Phase II clinical trials and completed the first dosing of a subject [1] - An IND application for LDR2515, a small nucleic acid drug for obesity treatment targeting INHBE, has received implied approval from the CDE [1] Group 2: Financial and Investment Details - Chengdu XianDao plans to invest up to 15 million yuan in XianYuan Biotech, which has a registered capital of 17.24 million yuan [1] - Prior to this transaction, Chengdu XianDao held a 23.20% stake in XianYuan Biotech and intends to subscribe to an additional capital increase of 24 million yuan based on a pre-investment valuation of 450 million yuan [1] - The lead investor in this financing round is Chengdu TianShi DaoYuan GuoSheng Medical Health Venture Capital Partnership, with other investors including related parties [1]

2026.02. 10 本文字数：855，阅读时长大约2分钟 作者 | 第一财经 钱童心 2月10日，阿斯利康公布2025年第四季度及全年财报。2025年，阿斯利康全球总营收达587.39亿 美元，同比增长8%，其中阿斯利康中国2025年总营收达66.54亿美元，同比增长4%，占总收入比 约11%，生物制药、肿瘤、罕见病三大业务领域均实现增长。 阿斯利康预测，2026年利润和销售将继续增长，这主要得益于癌症治疗和新药的需求。去年第四季 度，阿斯利康肿瘤药业务增长20%至70.3亿美元，但心血管业务受仿制药竞争影响下跌6%至30.5 亿美元。 阿斯利康CEO苏博科（Pascal Soriot）表示，2025年，阿斯利康宣布了16项积极的三期研究结 果，目前共有16种畅销药物。他还表示，公司今年预计还将公布超过20项三期试验结果，且还有 100多项三期临床试验正在进行中，包括多种创新技术疗法。 阿斯利康的目标是到2030年，年度销售额达到800亿美元，这一目标的实现将通过开发新药物和进 行投资来实现。公司计划到2030年推出20款全球创新药。 为此，阿斯利康正在推动在美国和中国的扩张。上个月，阿斯利康宣布从现在到 ...

Core Insights - AstraZeneca reported a total revenue of $58.739 billion for FY 2025, reflecting an 8% increase year-over-year, with China contributing $6.654 billion, a 4% increase, representing 11% of AstraZeneca's global market share [2][5]. Financial Performance - The five major business segments contributed as follows: Oncology ($25.619 billion, +14%), CVRM ($12.861 billion, +2%), Rare Diseases ($9.126 billion, +4%), Respiratory & Immunology ($8.866 billion, +12%), and Vaccines & Immune Therapies ($1.268 billion, -14%) [5][6]. - Notable products in the oncology segment included Tagrisso ($7.254 billion, +10%), Imfinzi ($6.063 billion, +28%), Calquence ($3.518 billion, +12%), and Lynparza ($3.279 billion, +6%) [6][7]. Strategic Developments in China - AstraZeneca announced plans to invest over 100 billion RMB in China by 2030, marking its largest investment in the country, aimed at enhancing drug R&D, manufacturing, and commercial innovation [12]. - The company has been actively expanding its investment in China, including a recent agreement to invest in respiratory drug production in Qingdao, bringing total investments in the area to $886 million [13]. - AstraZeneca's R&D pipeline in China has achieved a 100% synchronization rate with global efforts, with the Chinese team leading nearly 20 global clinical trials [13][14]. Collaborations and Partnerships - AstraZeneca has entered into significant collaborations, including a $12 billion strategic R&D partnership with CSPC Pharmaceutical Group, setting a record for upfront payments in China [13]. - Additional agreements include a global licensing deal for the KRAS inhibitor JAB-23E73 worth over $2 billion and a partnership with Hengrui Medicine to develop innovative therapies [14]. Market Positioning - AstraZeneca's strategic shift reflects a broader trend in the pharmaceutical industry, where China is increasingly viewed as a hub for innovation rather than just a market for sales and manufacturing [14].

Core Viewpoint - Yunnan Baiyao (000538.SZ) announced the construction of a second-phase project for oral liquid products to enhance production capacity and meet the growing market demand, aligning with the company's strategic goal of developing major product lines [1] Group 1 - The total investment budget for the new project is 137.36 million yuan [1] - The project aims to support the production of strategic large varieties within the group [1] - The initiative is part of the company's strategy to create a series of major single products [1]